AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04629404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Study NCT03678038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (Shincort) injection to rotator interval
Description: via rotator interval.
Study NCT03678038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Shincort) injection to posterior glenuhumeral recess
Description: via posterior glenuhumeral recess
Study NCT01806805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonegran
Study NCT01806805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zonegran
Study NCT01806805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT01806805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03595657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001
Description: monoclonal antibody
Study NCT01233505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO
Study NCT01233505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01233505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01233505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01233505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03733925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
Study NCT02995057 — intervention group
Intervention type: DEVICE
Intervention: Gold- or silver-coated, or uncoated nickel microneedles
Description: The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
Study NCT02808065 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Administered dose were individualized according to their own prescription
Study NCT02808065 — intervention group
Intervention type: DRUG
Intervention: Mycophenolate mofetil
Description: Administered dose were individualized according to their own prescription
Study NCT00339768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/omeprazole
Description: To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
Study NCT00604500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
Description: MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
Study NCT01619800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blended Sensor Optimization (BSO)
Description: At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized.
Study NCT01619800 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Accelerometer Alone (AA)
Description: Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
Study NCT04633109 — intervention group
Intervention type: PROCEDURE
Intervention: taste bud biopsy
Description: Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
Study NCT04633109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: 75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
Study NCT04633109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Taste sensitivity
Description: Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
Study NCT04633109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: olfactory function
Description: Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
Study NCT04633109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taste bud density
Description: The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
Study NCT04633109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometry
Description: Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
Study NCT04633109 — intervention group
Intervention type: OTHER
Intervention: biospecimen collection
Description: Blood and saliva samples will be taken as well as a tongue swab.
Study NCT04633109 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
Study NCT01357707 — intervention group
Intervention type: GENETIC
Intervention: DNA preparation
Description: Taking blood or saliva from the patient to prepare DNA therefrom
Study NCT05777707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Description: PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
Study NCT05777707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
Study NCT05777707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Nedaplatin
Description: Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
Study NCT02446626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Optional 2-3mm skin punch biopsies will be performed.
Study NCT02446626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Peripheral blood draws will be performed.
Study NCT02446626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenodiagnosis
Description: Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
Study NCT01938482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: Will be supplied as gel for topical application
Study NCT01938482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: Will be supplied as gel for topical application
Study NCT01938482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: Will be supplied as gel for topical application
Study NCT03263637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be administered as a intravenous (IV) infusion.
Study NCT01212874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
Study NCT01212874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esmolol
Description: esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
Study NCT00378690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin acetate
Description: LHRH antagonist
Study NCT00378690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin acetate
Description: LHRH antagonist
Study NCT01624064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5-20 mg/day
Study NCT01624064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Calcium 2.5-20 mg/day
Study NCT01038856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
Study NCT03648944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabillitation
Study NCT03648944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Accelerated Rehabillitation
Study NCT01494506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W
Study NCT01494506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 Fluorouracil
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
Study NCT01494506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
Study NCT01494506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Study NCT01494506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Study NCT01598701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
Study NCT02375503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00869180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical diclofenac patch applied once daily to area of pain
Study NCT00869180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Study NCT04139525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
Study NCT04139525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8% trisodium citrate
Description: 8% trisodium citrate in the dose of 150 ml/h.
Study NCT03176485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulator
Description: A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
Study NCT00656617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)
Study NCT00656617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
Study NCT00656617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
Study NCT03315949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Description: Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
Study NCT03315949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Description: Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
Study NCT01788514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Videogame
Description: Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
Study NCT02585206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalization
Description: Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data.
Study NCT02585206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integration
Description: Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online.
Study NCT02585206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Tailoring
Description: Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
Study NCT02585206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Message Intensity
Description: Phase I Factor~Varying levels of text message intensity over a 12-week period.
Study NCT02585206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal-Adherence Text
Description: Optimal-adherence text message intervention developed in Phase I
Study NCT02236377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
Study NCT02122419 — intervention group
Intervention type: OTHER
Intervention: lateral
Description: spinal anesthesia performed during lateral position
Study NCT02122419 — intervention group
Intervention type: OTHER
Intervention: sitting
Description: spinal anesthesia performed during sitting position
Study NCT03079830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study NCT03079830 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Piritramid
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study NCT03079830 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study NCT00984867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg tablet, oral, once daily, 48 weeks
Study NCT00984867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT01214122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 60 mg orally twice daily for 11 days
Study NCT01214122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 x 2.5 (25) mg orally once daily on day 1 and on day 14
Study NCT02515786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen humidification
Description: humidification for oxygen delivered by nasal catheter
Study NCT01374737 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: dexmedetomidine, 0.1ug/kg up or down
Study NCT01598701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL 0.9% Sodium Chloride
Study NCT02392793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
Study NCT02392793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given intravenously daily, days 2-6 immediately following the talazoparib dose.
Study NCT02392793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
Study NCT02392793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
Study NCT02392793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
Study NCT04444869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin injection
Description: Standard dose cisplatin given concurrently with radiation therapy
Study NCT00564356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery with phacoemulsification
Description: removal of cataract with phacoemulsification technique
Study NCT03552406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.
Study NCT03635125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol I
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
Study NCT03635125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol II
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
Study NCT03635125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Washout Phase
Description: 2 to 4 week Baseline Washout Phase